Lv11
50 积分 2025-03-20 加入
Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España
2小时前
待确认
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
2小时前
待确认
The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction
2小时前
待确认
PCSK9 is a predictive biomarker of major adverse events after acute myocardial infarction
2小时前
待确认
Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice
3小时前
待确认
皖公网安备34019202002308